Clinical Trials Logo

Stage IIIA Skin Melanoma clinical trials

View clinical trials related to Stage IIIA Skin Melanoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02748564 Terminated - Metastatic Melanoma Clinical Trials

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Start date: March 21, 2017
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving aldesleukin and pembrolizumab may kill more tumor cells. There are two parts to this study: - Phase Ib: To determine the safety and side effects of increasing doses of IL-2 in combination with pembrolizumab - Phase II: Once the maximum tolerated dose of IL-2 is determined, additional patients will be treated to determine if it is effective against the cancer.